Literature DB >> 10718415

Corticosteroid treatment for idiopathic facial nerve paralysis: a meta-analysis.

M J Ramsey1, R DerSimonian, M R Holtel, L P Burgess.   

Abstract

OBJECTIVE: A meta-analysis was designed to evaluate facial recovery in patients with complete idiopathic facial nerve paralysis (IFNP) by comparing outcomes of those treated with corticosteroid therapy with outcomes of those treated with placebo or no treatment. STUDY
DESIGN: Meta-analysis of prospective trials evaluating corticosteroid therapy for idiopathic facial nerve paralysis.
METHODS: A protocol was followed outlining methods for trial selection, data extraction, and statistical analysis. A MEDLINE search of the English language literature was performed to identify clinical trials evaluating steroid treatment of IFNP. Three independent observers used an eight-point analysis to determine inclusion criteria. Data analysis was limited to individuals with clinically complete IFNP. The endpoints measured were clinically complete or incomplete facial motor recovery. Effect magnitude and significance were evaluated by calculating the rate difference and Fisher's Exact Test P value. Pooled analysis was performed with a random effects model.
RESULTS: Forty-seven trials were identified. Of those, 27 were prospective and 20 retrospective. Three prospective trials met the inclusion criteria Tests of heterogeneity indicate the trial with the smallest sample size (RD = -0.19; 95% CI, -0.58-0.20), to be an outlier. It was excluded from the final analysis. Analyses of data from the remaining two studies indicate corticosteroid treatment improves complete facial motor recovery for individuals with complete IFNP. Rate difference demonstrates a 17% (990% CI, 0.01-0.32) improvement in clinically complete recovery for the treatment group based on the random effects model.
CONCLUSIONS: Corticosteroid treatment provides a clinically and statistically significant improvement in recovery of function in complete IFNP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718415     DOI: 10.1097/00005537-200003000-00001

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  16 in total

Review 1.  Recent developments in neurology.

Authors:  Samuel Wiebe; Michael W Nicolle
Journal:  BMJ       Date:  2002-03-16

Review 2.  Recent developments in Bell's palsy.

Authors:  N Julian Holland; Graeme M Weiner
Journal:  BMJ       Date:  2004-09-04

Review 3.  From evidence to action.

Authors:  Gary S Gronseth
Journal:  NeuroRx       Date:  2004-07

4.  For Bell's palsy, start steroids early; no need for an antiviral.

Authors:  Lisa Vargish; Sarah-Anne Schumann
Journal:  J Fam Pract       Date:  2008-01       Impact factor: 0.493

5.  [Idiopathic facial palsy during pregnancy].

Authors:  M Kunze; S Arndt; A Zimmer; M Földi; A Hanjalic-Beck; M Echternach; R Birkenhäger; A Aschendorff
Journal:  HNO       Date:  2012-02       Impact factor: 1.284

Review 6.  Acupuncture for Bell's palsy.

Authors:  Ning Chen; Muke Zhou; Li He; Dong Zhou; N Li
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

7.  Intra-aural tick resulting in facial nerve paresis.

Authors:  S Rajinder; N O Nik Adilah
Journal:  Malays Fam Physician       Date:  2017-12-31

8.  The expression of IL-2 and IL-4 in CD4(+) T cells from mouse lymph nodes and spleen during HSV-1-induced facial palsy.

Authors:  Lintao Gu; Yuechen Han; Wenwen Liu; Yanyan Mao; Jianfeng Li; Haibo Wang
Journal:  Inflamm Res       Date:  2013-11-27       Impact factor: 4.575

Review 9.  Corticosteroids for Bell's palsy (idiopathic facial paralysis).

Authors:  Vishnu B Madhok; Ildiko Gagyor; Fergus Daly; Dhruvashree Somasundara; Michael Sullivan; Fiona Gammie; Frank Sullivan
Journal:  Cochrane Database Syst Rev       Date:  2016-07-18

10.  Rodent facial nerve recovery after selected lesions and repair techniques.

Authors:  Tessa A Hadlock; Jeffrey Kowaleski; David Lo; Susan E Mackinnon; James T Heaton
Journal:  Plast Reconstr Surg       Date:  2010-01       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.